What I Peace does

I Peace, Inc. is a Palo Alto-headquartered biotech founded in 2015 by Koji Tanabe, a former researcher in Shinya Yamanaka's iPSC lab at Kyoto University. The company operates a CDMO-style iPSC manufacturing platform centered on its wholly-owned Peace Engine-Kyoto facility in Japan, which is licensed by Japan's MHLW, audited by the PMDA, third-party cGMP-certified against ICH-Q7 and FDA 21 CFR 210/211 and 1271, and registered as a U.S. FDA Drug Establishment (FEI 3020167797) with a Drug Master File on record.

The company's core differentiator is a proprietary fully closed automated iPSC manufacturing system co-developed with FANUC CORPORATION, in which palm-sized closed cassettes perform the full reprogramming sequence on a miniaturized plate assisted by robotic technology. This architecture enables mass parallel production of clinical-grade iPSC lines from multiple donors in a single GMP room while eliminating cross-contamination risk, and has reduced direct manufacturing cost of a clinical-grade iPSC line from a historical $1M+ benchmark to several tens of thousands of dollars. Specialty platforms layered on top include HLA-homozygous iPSC lines covering 35.91% of the U.S. population, universal cells with multiple HLA genes removed for allogeneic transplantation, NKT cell-derived iPSCs, and direct reprogramming methods (jointly with Stanford and UCSF) for disease modeling.

I Peace operates three coordinated revenue lines: (1) GMPeace, a GMP CDMO service for pharmaceutical and biotech customers (custom iPSC lines, master/working cell banks, differentiated cell products); (2) research-grade iPSC products and services for academic and drug-discovery customers; and (3) My Peace, a personal iPSC banking subscription service sold D2C and via the I'rom Group (2,245 medical facilities) and SBI Wellness Bank distribution channels. Pricing is quote-based for enterprise services, while personal banking has historically been priced at approximately 2 million yen per customer. Named customers include Avery Therapeutics, Heartseed, iCamuno Biotherapeutics, and Vita Therapeutics, alongside the CIRM Industry Resource Partner Program for U.S. research pipeline access.

Name

I Peace

Legal name

I Peace, Inc.

Website

https://ipeace.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

I Peace is a Palo Alto-based biotech operating an FDA-registered, cGMP-certified iPSC manufacturing platform in Kyoto that delivers GMP and research-grade iPSC CDMO services, off-the-shelf allogeneic lines, and the My Peace personal iPSC banking subscription to pharma, biotech, and consumer customers globally.

Ownership category

akta.pro rank

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. GMP iPSC CDMO / Contract Manufacturing: Contract Development and Manufacturing Organization services providing clinical-grade iPSC manufacturing, iPSC master cell banks, working cell banks, and iPSC-derived differentiated cell products for pharmaceutical companies and cell therapy developers.
2. Custom iPSC Generation Service (clinical/research grade): Custom manufacturing of iPSCs from client-sourced materials or sourced donors meeting client-specified criteria. Project-based transactions for clinical-grade and research-grade iPSC generation.
3. My Peace - Personal iPSC Banking: Personal iPSC banking service offering long-term storage of individuals' iPS cells for future regenerative medicine. Recurring/repeat service model with personalized banking subscriptions.
4. Off-the-shelf GMP iPSC line sales: Sale of pre-manufactured off-the-shelf allogeneic GMP iPSC lines (including HLA homozygous and universal cell lines) to research institutions and pharmaceutical companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels7 records

Core offering

I Peace provides contract manufacturing and sale of clinical-grade (GMP) and research-grade induced pluripotent stem cell (iPSC) products through its proprietary fully closed automated Peace Engine manufacturing system. The company serves pharmaceutical companies, biotech firms, and academic institutions with custom iPSC generation, master/working cell banks, and iPSC-derived differentiated cell products, while also offering a direct-to-consumer personal iPSC banking service called My Peace for individuals banking their own cells for future regenerative medicine.

Product overview

I Peace operates a CDMO-style platform offering three coordinated product/service lines for clinical-grade and research-grade induced pluripotent stem cell (iPSC) manufacturing, anchored by its GMP manufacturing facility "Peace Engine-Kyoto" in Kyoto, Japan. The core offerings comprise (1) GMPeace (GMP cell products and services) for pharmaceutical and biotech customers, (2) Research-Grade iPSC products and services for academic and drug discovery customers, and (3) My Peace, the personal iPSC banking service for individuals. The platform is differentiated by a proprietary fully closed, miniaturized, robotic mass-production system co-developed with FANUC CORPORATION that enables simultaneous parallel manufacture of discrete clinical-grade iPSC lines from multiple donors in a single GMP room, dramatically reducing manufacturing cost. Specialty product lines include HLA Homozygous GMP iPSC Lines (Low Immunoreaction Risk) for allogeneic therapy, Universal Cells (HLA-edited allogeneic iPSCs) co-developed with Vita Therapeutics for FSHD, NKT cell-derived iPSCs for immune cell applications, and differentiated cell products generated via direct reprogramming. The next-generation "EGG" device displayed at the 2025 Osaka-Kansai Expo represents the company's roadmap for fully automated end-to-end iPSC and differentiated cell production in a single unit.

Differentiator

Problem solved

Functional benefit

Brands

• My Peace: Personal iPSC banking service for individuals to bank their own iPS cells for future regenerative medicine and personalized medicine applications. Also marketed under the Japanese name MyPeace.
• GMP細胞製品・サービス (GMP Products & Services)
• 研究用細胞製品・サービス (Research-Grade Products & Services)
• Reju

Products and services

• My Peace Personal iPSC Banking Service Direct-to-consumer personal iPSC banking service where individuals bank their own iPS cells for future regenerative medicine applications. Cells are manufactured in Japan at the Peace Engine-Kyoto facility and stored for long-term personalized medicine use. Available in Japan and the United States.
• GMPeace - GMP Cell Products & Services Clinical-grade (GMP) iPSC manufacturing service for pharmaceutical companies, biotech firms, and research institutions. Provides custom manufacturing, master/working cell banks, and iPSC-derived differentiated cell products meeting Japanese MHLW/PMDA and U.S. FDA standards (cGMP, ICH-Q7, 21 CFR 210/211, 21 CFR 1271).
• Research-Grade iPSC Products & Services Research-grade iPSC and iPSC-derived differentiated cell products and services for academic institutions and pharmaceutical companies conducting drug discovery, disease modeling, and screening research.
• HLA Homozygous GMP iPSC Lines (Low Immunoreaction Risk) Allogeneic HLA-homozygous GMP iPSC lines engineered for low immunoreaction risk, intended for off-the-shelf allogeneic cell therapy to reduce immune rejection. Lines collectively cover 35.91% of the U.S. population.
• Universal Cells (HLA-Edited Allogeneic iPSCs) Allogeneic iPSC-derived universal cells with multiple HLA genes removed to suppress immune rejection after transplantation. Developed jointly with Vita Therapeutics for FSHD cell transplantation therapy.
• Human iPS Cells Derived from NKT Cells NKT cell-derived human iPSCs offering highly uniform and reproducible immune cell-derived iPSC lines for research use. Generated using proprietary selective NKT cell expansion and clonal line generation technology; uniformity confirmed via genomic PCR analysis.
• iPSC-Derived Differentiated Cell Products (Direct Reprogramming) Direct reprogramming services for converting human dermal fibroblasts directly into functional target cells (e.g., oligodendrocyte precursor cells) without passing through an iPSC intermediate. Jointly developed with Stanford University and UCSF; used for drug discovery and disease modeling.

Named customers9 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Eleven partnerships are on record, tiered core, minor and flagship.

• SBI Wellness Bank (SBI Holdings subsidiary)coreChannel Partner/ Reseller/ Distributor · 25 June 2025Collaboration to expand My Peace personal iPSC banking service leveraging SBI Wellness Bank's medical network, including partner medical institution T.O.P. Doctors Tokyo International Clinic. Built on cooperation between SBI Holdings and I Peace from the 2025 Osaka-Kansai Expo where SBI sponsored the Osaka Healthcare Pavilion. Combines I Peace's world-class iPSC manufacturing/storage technology with SBI Wellness Bank's health management and preventive medical services.
• Funroots Co., Ltd.minorStrategic or Co-development Partner · 7 May 2025Three-party strategic alliance with Reju, Inc. to bring iPS cell technology to the sports field. Aimed at soccer player injury treatment and prevention, performance improvement using iPS cell-related technology, and educational/outreach activities. Funroots brings global soccer industry network including connections with stars like Messi, Neymar, and João Félix.
• Reju, Inc. (I Peace group company)minorStrategic or Co-development Partner · 7 May 2025Three-party strategic alliance with Funroots. Reju is an I Peace group company that developed iPSF (iPS cell extract component), aiming to leverage iPS cell technology in the sports industry for health and beauty applications.
• SBI HoldingscoreGTM or Marketing Partner · 27 March 2025Cooperation at the 2025 Osaka-Kansai Expo: SBI Holdings sponsored the Osaka Healthcare Pavilion "Nest for Reborn" with a booth themed "街のネオホスピタル" (Neo Hospital of the Town) modeled after a 2050 hospital; I Peace participated as a cooperating company exhibiting its next-generation iPSC manufacturing device "EGG".
• Vita TherapeuticsflagshipStrategic or Co-development Partner · 28 February 2025Joint co-development of universal cell transplantation therapy for FSHD (facioscapulohumeral muscular dystrophy). I Peace contributes its GMP iPSC-related technology; Vita contributes its cell transplantation therapy technology for FSHD. The approach uses universal cells created from allogeneic iPSCs with multiple HLA genes removed to suppress immune rejection. Vita is an early-stage startup focused on iPSC-derived therapies for muscular diseases.
• iCamuno BiotherapeuticscoreStrategic or Co-development Partner · 23 August 2024Stem cell therapy developers I Peace and iCamuno Biotherapeutics started a Natural Killer (NK) Cell Trial for Ovarian Cancer. I Peace supplies iPSCs as the starting material for NK cell manufacturing.
• California Institute for Regenerative Medicine (CIRM)flagshipStrategic or Co-development Partner · 1 November 2022I Peace joined the CIRM Industry Resource Partner Program to provide GMP iPSCs for various research programs funded by CIRM. I Peace provides research-grade iPSCs derived from GMP iPSCs to CIRM's Discovery pursuit stage research projects and GMP manufacturing services for CIRM Translational and Clinical Stage projects. CIRM is supported by $5.5 billion in California state funding, has funded 82 clinical trials, and backs 152+ active regenerative medicine research projects.
• Genequest Inc.coreTechnology or Integration · 12 May 2022Data-driven collaboration to identify potential cell donors with specific HLA haplotypes. Combining Genequest's inventory of genomic information of tens of thousands of customers with I Peace's mass production capability of GMP iPSCs. Already identified 1,547 HLA-homozygous potential donors and generated iPSCs. Algorithm accuracy above 93% verified through high-resolution, next-generation sequencing-based HLA haplotyping from seven people.
• I'rom GroupcoreChannel Partner/ Reseller/ Distributor · 21 July 2021Partnership agreement to provide personal medical-use iPSC production and storage services through I'rom Group's blood-derived medical-use iPSC bank business "iCELL BANK". Leverages I'rom Group's nationwide medical network of 2,245 medical facilities to extend My Peace service across Japan. The personal medical-use iPSC production and storage service is manufactured in facilities with specific cell processing product manufacturing permits under strict management for medical use, compliant with both Japanese and US regulations.
• Avery TherapeuticsflagshipStrategic or Co-development Partner · 28 December 2020I Peace will provide GMP-grade iPSCs and key technology/services to Avery Therapeutics under a service contract to develop MyCardia, an engineered tissue sheet for heart failure treatment. I Peace's Kyoto GMP facility (PMDA and USFDA compliant) produces the iPSCs; commercial-use donor recruitment and iPSC production are IRB-approved. This collaboration marks I Peace's first major US biotech partnership for cardiac cell therapy.
• FANUC CORPORATIONflagshipTechnology or Integration · 15 July 2020Joint development of I Peace's fully closed automated iPSC mass manufacturing system in a palm-sized closed cassette. FANUC provides robotics and automation expertise (headquartered in Oshino, Yamanashi Prefecture, Japan; CEO Kenji Yamaguchi); I Peace contributes biotechnology and iPSC manufacturing know-how. The modular and scalable system enables simultaneous mass production of clinical-grade iPSCs from multiple donors in a single facility.

Scale indicators11 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• FUJIFILM Cellular Dynamics: FUJIFILM Cellular Dynamics is a leading commercial supplier of iPSC-derived cells and iPSC manufacturing services, offering both research-grade and clinical-grade iPSC lines, master cell banks, and differentiation services. Directly comparable to I Peace as an iPSC-focused CDMO serving pharma, biotech, and academic customers, but with the backing of FUJIFILM's significantly larger global manufacturing footprint and bioprocess capabilities.
• Lonza Cell & Gene Technologies: Lonza is the world's largest contract development and manufacturing organization for cell and gene therapies, offering iPSC process development, GMP manufacturing, and commercial-scale production through its Cocoon and other platforms. Comparable to I Peace as a clinical-grade cell therapy CDMO, but at vastly greater scale, broader modality coverage (autologous and allogeneic), and a global multi-site footprint.
• Catalent Cell & Gene Therapy: Catalent is a major global CDMO offering cell therapy development and manufacturing services, including iPSC-related process development and clinical/commercial supply across multiple sites. Comparable to I Peace as a clinical-grade cell therapy CDMO, though Catalent operates at materially larger scale and broader modality.

Direct peers

• ReproCELL: ReproCELL (now part of Veritas Bio) is a Japan-headquartered stem cell technology company offering iPSC generation services, research-grade iPSC products, and regenerative medicine tools. Directly comparable to I Peace in terms of Japan-based clinical-grade iPSC CDMO positioning, research-grade catalog products, and service orientation to pharma/academic customers.
• CellGenix: CellGenix is a German-headquartered GMP manufacturer of cell and gene therapy ancillary materials and contract manufacturing services, including iPSC-related process development and GMP production. Comparable to I Peace as a clinical-grade cell therapy manufacturing partner with a similar focus on quality, regulatory compliance (FDA/EMA), and serving pharma/biotech customers.
• RoslinCT: RoslinCT is a Scotland-based contract development and manufacturing organization specializing in cell and gene therapies, including iPSC-derived cell therapy manufacturing for clinical and commercial supply. Comparable to I Peace as a specialist GMP cell therapy CDMO serving clinical-stage biotech customers with similar regulatory complexity and quality requirements.

Emerging players

• Century Therapeutics: Century Therapeutics is a clinical-stage biotech developing allogeneic iPSC-derived immune cell therapies (NK and T cells) with engineered features to avoid immune rejection. Comparable to I Peace around the application of HLA-edited and engineered iPSC platforms for off-the-shelf cell therapy, though Century is a therapy developer rather than a CDMO.
• Fate Therapeutics: Fate Therapeutics is a clinical-stage biotech developing off-the-shelf iPSC-derived cell therapies for cancer and autoimmune diseases, with proprietary iPSC platform and clonal master cell bank approach. Comparable to I Peace around the off-the-shelf iPSC paradigm for allogeneic cell therapy, and as a major consumer of clinical-grade iPSC manufacturing capacity.
• Cynata Therapeutics: Cynata Therapeutics is an Australian clinical-stage company developing iPSC-derived mesenchymal stem cell (MSC) therapies using its Cymerus platform. Comparable to I Peace as a clinical-stage developer leveraging iPSC manufacturing technology for off-the-shelf cell therapy commercialization.

Regional players

• MEDINET (Medinet Co., Ltd.): MEDINET is a Japanese cell therapy contract manufacturer offering GMP cell processing and somatic stem cell services, primarily serving Japan-based regenerative medicine developers. Comparable to I Peace as a Japan-based cell therapy CDMO with similar MHLW/PMDA regulatory orientation and customer base, though with focus on somatic rather than iPSC cell therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/IPeaceInc_E
• Facebookfacebook.com/ipeace.inc
• LinkedInlinkedin.com/company/i-peace-inc.
• Instagraminstagram.com/mypeace_ips

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about I Peace